|Bid||0.00 x 1300|
|Ask||0.00 x 4000|
|Day's Range||43.50 - 44.46|
|52 Week Range||41.45 - 56.32|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||8.11|
|Forward Dividend & Yield||1.64 (3.73%)|
|Ex-Dividend Date||Jan 26, 2023|
|1y Target Est||N/A|
NEW YORK, January 31, 2023--Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
DAVOS, Switzerland, January 17, 2023--Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.
NEW YORK, January 06, 2023--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine in infants and children 6 weeks through 17 years of age, and for the prevention of ot